



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, May 12th, 2016
7:15 a.m. to 8:15 a.m.
Cannon Health Building
Room 125

Board Members Present

Jay Aldus, D.D.S	Jennifer Brinton, M.D., Board Chair
Michael Symond, M.D.	Susan Siegfroid, M.D
Neal Catalano, Pharm.D.	Steve Lore, M.D
Holly Gurgle, Pharm.D.	Katherine Smith, Pharm.D.
Kumar Shah, M.Sc., P.Eng.	

Board Members Excused:

Keith Tolman, M.D	Ben Berrett, Pharm D
-------------------	----------------------

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm.D.	Heather Santacruz, R.N.
Alyssa Pitts, R.N.	Bryan Larson, Pharm.D.
Merelynn Berrett, R.N	Megan Schlappi, C.Ph.T.

Other Individuals Present:

Joanita Lake, UofU*	Gary Oderda, UofU
Lori Howarth, Bayer	Kelvin Yamashita, Sanofi
Robert Nohavec, Healthy U	

*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

1. **Welcome & Housekeeping:** Jennifer Brinton opened the meeting and reminded everyone to sign in. She also reminded the board that there will not be a meeting held in June. Chad Hope summarized the Utah Code for scribing the minutes, as a motion had been made at the previous DUR meeting to follow Robert's Rules of Order.

a. Kumar Shah motioned to approve the minutes in line with Utah Code from March and April. Neal Catalano seconded. All in favor.

2. **9 Month Review: Avedd, Natesto, Volgelxo:** Chad Hope said that the previously set criteria on these medications is working well with no problems.

3. **Reconsideration of PA Criteria:** The Board reviewed outdated clinical PA criteria on 9 medications. They motioned to remove the PA's for the following medications: Amitiza, Ziana, Zovirax Ointment, Terbinafine, Xolegel, Olux, and Luxiq. Mike Symond made the motion to remove the PA criteria. Neal Catalano seconded. All in favor. Susan Siegfroid made a motion not to remove the clinical PA's on Nucynta or Nucynta ER. Kumar Shah seconded. All in favor.

4. **Xyrem:** Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the three androgen products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.

5. **Public Comments:** N/A

6. **Board Discussion**

- a. Neal Catalano and Jennifer Brinton had concerns with the old PA criteria on Xyrem and why it was not following the REMS guidelines.
- b. Susan Siegfried explained to the board that there are different types of narcolepsy and different medications to try for each diagnosis.
- c. The board had concerns with who was prescribing Xyrem, as it appeared that a lot of family practitioners were prescribing it. Susan Siegfried suggested that the PA criteria include the words “prescribed by or in consultation with a physician that is board certified in sleep medicine”.
- d. The board discussed if people with excessive daytime sleepiness (EDS) should have access to Xyrem. Chad Hope told the board that they should cover a medication for any indication in which it has been FDA approved. Holly Gurgle stated that in other PA criteria she has seen, they do cover Xyrem for the indication of EDS after they have gone through step therapy.
- e. Step therapy for the indication of EDS was discussed in detail.
- f. Katherine Smith recommended that the board remove any age limits on the PA criteria, as there are studies and uses for children.
- g. The board discussed how long the PA should be good for initially and after reauthorization.
- h. Mike Symond made a motion to approve the final draft of the PA criteria. Katherine Smith seconded. All in favor. The final PA criteria is as follows:
 - Prescribed by or in consultation with a physician that is board certified in sleep medicine
 - Diagnosis of cataplexy associated with narcolepsy **OR** diagnosis of excessive daytime sleepiness with narcolepsy and failed previous treatments with either modafinil or armodafinil **AND** a stimulant.
 - Maximum Approved dose: 9gm/day
 - Authorization: 1 month
 - Re-Authorization: Every 3 months with follow-up visit

7. **Public Meeting Adjourned**

8. **Next meeting is scheduled for July 14th, 2016. Opiates, short acting and combination products will be discussed.**

Minutes prepared by Megan Schlappi, CPhT

Recording available upon request, send email to medicaidpharmacy@utah.gov